<p>Adicet Bio（納斯達克：ACET - 獲取免費報告）的股票在週四的研究報告中被 Wedbush 重申了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 5.00 美元。</p>
<p>其他幾位分析師也對 ACET 發佈了報告。HC Wainwright 在 7 月 23 日的研究報告中將 Adicet Bio 的股票評級上調至 “強力買入”，並設定了 4.00 美元的目標價。Weiss Ratings 在 10 月 30 日的研究報告中重申了 Adicet Bio 的 “賣出（d-）” 評級。Guggenheim 在 10 月 8 日的研究報告中將 Adicet Bio 的目標價從 7.00 美元上調至 8.00 美元，並給予該股票 “買入” 評級。最後，Jefferies Financial Group 在 10 月 7 日的報告中將 Adicet Bio 的股票評級上調至 “強力買入”。兩位股票研究分析師給予該股票 “強力買入” 評級，兩位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 5.67 美元。</p>
<p><strong>閲讀我們關於 ACET 的最新報告</strong></p>
<h2>Adicet Bio 股票表現</h2>
<p>週四，納斯達克 ACET 的股價下跌 0.01 美元，達到 0.68 美元。該公司的股票交易量為 846,724 股，而其平均交易量為 897,070 股。該股票的市值為 5653 萬美元，市盈率為-0.52，貝塔值為 1.61。Adicet Bio 的 12 個月低點為 0.45 美元，12 個月高點為 1.40 美元。該公司的 50 日移動平均線為 0.84 美元，200 日移動平均線為 0.74 美元。</p>
<p>Adicet Bio（納斯達克：ACET - 獲取免費報告）最後一次公佈季度財報是在 11 月 5 日。該公司報告的每股收益為（0.29 美元），低於分析師的共識預期（0.26 美元）0.03 美元。股票研究分析師預計 Adicet Bio 在當前財政年度的每股收益為-1.39 美元。</p>
<h2>機構投資者對 Adicet Bio 的看法</h2>
<p>機構投資者和對沖基金最近對該股票的持倉進行了調整。高盛集團在第一季度將其在 Adicet Bio 的持股比例提高了 1.7%。高盛集團目前擁有 3816556 股該公司的股票，價值 288.2 萬美元，此前在此期間又收購了 63691 股。Acadian Asset Management LLC 在第一季度將其在 Adicet Bio 的持倉提高了 1.8%。Acadian Asset Management LLC 目前擁有 2039324 股該公司的股票，價值 153.8 萬美元，此前在上個季度又購買了 36277 股。Wealthedge Investment Advisors LLC 在第二季度將其在 Adicet Bio 的持股比例提高了 37.4%。Wealthedge Investment Advisors LLC 目前擁有 313108 股該公司的股票，價值 19.1 萬美元，此前在上個季度又購買了 85307 股。最後，Vontobel Holding Ltd.在第二季度將其在 Adicet Bio 的持股比例提高了 33.3%。Vontobel Holding Ltd.目前擁有 80000 股該公司的股票，價值 49000 美元，此前在上個季度又收購了 20000 股。機構投資者持有該公司 83.89% 的股票。</p>
<h2>關於 Adicet Bio</h2>
<p>（獲取免費報告）</p>
<p>Adicet Bio, Inc 是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法。該公司提供經過嵌合抗原受體（CAR）工程化的伽馬δ T 細胞，以促進患者的持久活性。其主要產品候選藥物是 ADI-001，這是一種表達針對 CD20 的 CAR 的異體伽馬δ T 細胞療法，目前正在進行針對自身免疫疾病和復發或難治性侵襲性 B 細胞非霍奇金淋巴瘤的 I 期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Adicet Bio 更好</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Tempus AI：波動性等同於 AI 領導者的機會</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>跟隨資金：三隻機構持股比例高的股票</li>
<li>投資的股票類型各不相同</li>
<li>黃金礦業股票能否在金屬反彈減弱時發光？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNFVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNFVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Adicet Bio 嗎？</h2>
<p>在你考慮 Adicet Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Adicet Bio 並不在名單上。</p>
<p>雖然 Adicet Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ACET

<p>Wedbush 重申了對 Adicet Bio（NASDAQ: ACET）的 “跑贏大盤” 評級，目標價為 5.00 美元。其他分析師的意見各不相同，HC Wainwright 將評級上調至 “強力買入”，目標價為 4.00 美元，而 Weiss Ratings 則維持 “賣出” 評級。該股票目前交易價格為 0.68 美元，市值為 5653 萬美元。Adicet Bio 專注於開發針對自身免疫疾病和癌症的伽馬δ T 細胞療法，其主要候選藥物正在進行 I 期臨牀試驗</p>

<p>Adicet Bio (NASDAQ:ACET - Get Free Report)'s stock had its &#34;outperform&#34; rating restated by Wedbush in a research note issued on Thursday,RTT News reports. They currently have a $5.00 price objective on the stock.</p>
<div class="lb-trans"><p>Adicet Bio（納斯達克：ACET - 獲取免費報告）的股票在週四的研究報告中被 Wedbush 重申了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 5.00 美元。</p>
</div><p>Several other analysts have also issued reports on ACET. HC Wainwright upgraded shares of Adicet Bio to a &#34;strong-buy&#34; rating and set a $4.00 price target on the stock in a research report on Wednesday, July 23rd. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Adicet Bio in a research note on Thursday, October 30th. Guggenheim raised their target price on Adicet Bio from $7.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group raised shares of Adicet Bio to a &#34;strong-buy&#34; rating in a report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $5.67.</p>
<div class="lb-trans"><p>其他幾位分析師也對 ACET 發佈了報告。HC Wainwright 在 7 月 23 日的研究報告中將 Adicet Bio 的股票評級上調至 “強力買入”，並設定了 4.00 美元的目標價。Weiss Ratings 在 10 月 30 日的研究報告中重申了 Adicet Bio 的 “賣出（d-）” 評級。Guggenheim 在 10 月 8 日的研究報告中將 Adicet Bio 的目標價從 7.00 美元上調至 8.00 美元，並給予該股票 “買入” 評級。最後，Jefferies Financial Group 在 10 月 7 日的報告中將 Adicet Bio 的股票評級上調至 “強力買入”。兩位股票研究分析師給予該股票 “強力買入” 評級，兩位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 5.67 美元。</p>
</div><p><strong>Read Our Latest Report on ACET</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ACET 的最新報告</strong></p>
</div><h2>Adicet Bio Stock Performance</h2>
<div class="lb-trans"><h2>Adicet Bio 股票表現</h2>
</div><p>NASDAQ ACET traded down $0.01 on Thursday, reaching $0.68. The company's stock had a trading volume of 846,724 shares, compared to its average volume of 897,070. The stock has a market cap of $56.53 million, a PE ratio of -0.52 and a beta of 1.61. Adicet Bio has a twelve month low of $0.45 and a twelve month high of $1.40. The firm's 50 day moving average is $0.84 and its two-hundred day moving average is $0.74.</p>
<div class="lb-trans"><p>週四，納斯達克 ACET 的股價下跌 0.01 美元，達到 0.68 美元。該公司的股票交易量為 846,724 股，而其平均交易量為 897,070 股。該股票的市值為 5653 萬美元，市盈率為-0.52，貝塔值為 1.61。Adicet Bio 的 12 個月低點為 0.45 美元，12 個月高點為 1.40 美元。該公司的 50 日移動平均線為 0.84 美元，200 日移動平均線為 0.74 美元。</p>
</div><p>Adicet Bio (NASDAQ:ACET - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.03). Equities research analysts anticipate that Adicet Bio will post -1.39 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Adicet Bio（納斯達克：ACET - 獲取免費報告）最後一次公佈季度財報是在 11 月 5 日。該公司報告的每股收益為（0.29 美元），低於分析師的共識預期（0.26 美元）0.03 美元。股票研究分析師預計 Adicet Bio 在當前財政年度的每股收益為-1.39 美元。</p>
</div><h2>Institutional Investors Weigh In On Adicet Bio</h2>
<div class="lb-trans"><h2>機構投資者對 Adicet Bio 的看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its stake in Adicet Bio by 1.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company's stock valued at $2,882,000 after acquiring an additional 63,691 shares during the period. Acadian Asset Management LLC lifted its position in shares of Adicet Bio by 1.8% during the first quarter. Acadian Asset Management LLC now owns 2,039,324 shares of the company's stock valued at $1,538,000 after purchasing an additional 36,277 shares in the last quarter. Wealthedge Investment Advisors LLC grew its stake in Adicet Bio by 37.4% in the 2nd quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company's stock valued at $191,000 after buying an additional 85,307 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its stake in Adicet Bio by 33.3% in the 2nd quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company's stock worth $49,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors own 83.89% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該股票的持倉進行了調整。高盛集團在第一季度將其在 Adicet Bio 的持股比例提高了 1.7%。高盛集團目前擁有 3816556 股該公司的股票，價值 288.2 萬美元，此前在此期間又收購了 63691 股。Acadian Asset Management LLC 在第一季度將其在 Adicet Bio 的持倉提高了 1.8%。Acadian Asset Management LLC 目前擁有 2039324 股該公司的股票，價值 153.8 萬美元，此前在上個季度又購買了 36277 股。Wealthedge Investment Advisors LLC 在第二季度將其在 Adicet Bio 的持股比例提高了 37.4%。Wealthedge Investment Advisors LLC 目前擁有 313108 股該公司的股票，價值 19.1 萬美元，此前在上個季度又購買了 85307 股。最後，Vontobel Holding Ltd.在第二季度將其在 Adicet Bio 的持股比例提高了 33.3%。Vontobel Holding Ltd.目前擁有 80000 股該公司的股票，價值 49000 美元，此前在上個季度又收購了 20000 股。機構投資者持有該公司 83.89% 的股票。</p>
</div><h2>About Adicet Bio</h2>
<div class="lb-trans"><h2>關於 Adicet Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.</p>
<div class="lb-trans"><p>Adicet Bio, Inc 是一家臨牀階段的生物技術公司，專注於發現和開發用於自身免疫疾病和癌症的異體伽馬δ T 細胞療法。該公司提供經過嵌合抗原受體（CAR）工程化的伽馬δ T 細胞，以促進患者的持久活性。其主要產品候選藥物是 ADI-001，這是一種表達針對 CD20 的 CAR 的異體伽馬δ T 細胞療法，目前正在進行針對自身免疫疾病和復發或難治性侵襲性 B 細胞非霍奇金淋巴瘤的 I 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Adicet Bio</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Tempus AI: Volatility Equates to Opportunity in AI Leader</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Follow the Money: 3 Stocks With High Institutional Ownership</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Can Gold Mining Stocks Shine as the Metals Rally Falters?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Adicet Bio 更好</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Tempus AI：波動性等同於 AI 領導者的機會</li>
<li>成長股：它們是什麼，示例及如何投資</li>
<li>跟隨資金：三隻機構持股比例高的股票</li>
<li>投資的股票類型各不相同</li>
<li>黃金礦業股票能否在金屬反彈減弱時發光？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNFVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ACET"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adicet Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Adicet Bio 嗎？</h2>
</div><p>Before you consider Adicet Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Adicet Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Adicet Bio 並不在名單上。</p>
</div><p>While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adicet Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Wedbush 重申了對 Adicet Bio（ACET）的 “表現優於大盤” 評級